Health Care·Biotechnology·$10.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.09 | N/A | +1600.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.09 | N/A | +1600.00% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their pipeline and is pleased with the unexpected EPS results. However, they did not provide specific guidance for future quarters.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing efforts in research and development as a priority.
BioMarin's earnings report showed a significant surprise in EPS, which indicates better-than-expected profitability. However, the stock reacted negatively, declining by 0.6%. This could suggest that investors were looking for more comprehensive revenue information or future guidance, which was not provided.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HONEYWELL INTL INC
Jul 27, 2009